End Oil and Gas Tax Subsidies Act of 2025

House Bill

H.R. 383

119th Congress

End Oil and Gas Tax Subsidies Act of 2025

In Committee

Introduced:Jul 22, 2025

Primary Sponsor

David P. Joyce

Representative

Republican

OH-14

Cosponsors

26

Quick Stats

Policy Area

Health

Summary

This bill aims to reverse recent changes made by the FDA to the rules around how the abortion pill mifepristone can be prescribed and distributed. If passed, it would require mifepristone to only be dispensed directly to patients in clinics, medical offices, or hospitals, rather than allowing it to be sent by mail from pharmacies.

Latest Action

Referred to the Subcommittee on Health.

SponsorDavid P. Joyce (R-OH)

Introduced7/22/2025

StatusReferred to the House Committee on Ways and Means.

ChamberHouse

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

End Oil and Gas Tax Subsidies Act of 2025

This bill aims to reverse recent changes made by the FDA to the rules around how the abortion pill mifepristone can be prescribed and distributed. If passed, it would require mifepristone to only be dispensed directly to patients in clinics, medical offices, o

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill aims to reverse recent changes made by the FDA to the rules around how the abortion pill mifepristone can be prescribed and distributed. If passed, it would require mifepristone to only be dispensed directly to patients in clinics, medical offices, or hospitals, rather than allowing it to be sent by mail from pharmacies.

Bill Number: 383
Sponsor: David P. Joyce (R-OH)
Introduced: 7/22/2025
Status: Referred to the House Committee on Ways and Means.
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: End Oil and Gas Tax Subsidies Act of 2025
Bill Number: 383
Sponsor: David P. Joyce (R-OH)
Status: Referred to the House Committee on Ways and Means.
Introduced: 7/22/2025
Summary: This bill aims to reverse recent changes made by the FDA to the rules around how the abortion pill mifepristone can be prescribed and distributed. If passed, it would require mifepristone to only be dispensed directly to patients in clinics, medical offices, or hospitals, rather than allowing it to

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill aims to reverse recent changes made by the FDA to the rules around how the abortion pill mifepristone can be prescribed and distributed. If passed, it would require mifepristone to only be dispensed directly to patients in clinics, medical offices, or hospitals, rather than allowing it to be sent by mail from pharmacies.

Last updated: 12/30/2025

Official Summary

Congressional Research Service summary

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

Key Points

Main provisions of the bill

The bill nullifies recent FDA changes that allowed mifepristone to be dispensed by certified pharmacies rather than only in-person at clinics.
It would prohibit the FDA from making similar changes in the future to ease access to the abortion pill.
The changes the bill seeks to undo were made to increase access to medication abortion during the COVID-19 pandemic.

How This Impacts Americans

Potential effects on citizens and communities

If this bill becomes law, it would make it more difficult for people to access mifepristone, the medication used for early abortion. This would primarily impact people seeking medication abortions, especially those in rural or underserved areas who may have to travel long distances to reach a certified clinic. Pharmacies and healthcare providers would also be affected, as they would lose the ability to easily provide or dispense this medication.

Policy Areas

Primary Policy Area

Health

Related Subjects

Abortion

Drug safety, medical device, and laboratory regulation

Drug therapy

Prescription drugs

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

383, 119th Congress (2025). "End Oil and Gas Tax Subsidies Act of 2025". Source: Voter's Right Platform. https://votersright.org/bills/118-hr-383

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.